Table 4.
Morphea Subtype/Autoantibody |
P Value
|
||||||
---|---|---|---|---|---|---|---|
Limited Function | BSAb | mRSS | Localized Scleroderma Skin
|
PGA
|
|||
Severity Index | Damage Index | Activity | Damage | ||||
Linear | |||||||
| |||||||
ANA | NS | .005 | <.001 | NS | NS | NS | NS |
| |||||||
Anti-ssDNA | .005 | .01 | NS | NS | NS | NS | NS |
| |||||||
Antihistone | .006 | NS | NS | NS | NS | NS | NS |
| |||||||
Total group of patients with morphea | |||||||
| |||||||
ANA | NS | NS | <.001 | NS | NS | NS | NS |
| |||||||
Anti-ssDNA | .03 | NS | NS | NS | NS | NS | NS |
| |||||||
Antihistone | .007 | NS | NS | NS | NS | NS | NS |
Abbreviations: ANA, antinuclear antibody; Anti-ssDNA, anti–single-stranded DNA; BSA, body surface area; mRSS, modified Rodnan Skin Score; NS, nonsignificant; PGA, Physician Global Assessment.
Only subtypes with statistically significant associations are shown. Generalized and plaque subtypes do not have any significant associations.
Extensive BSA is defined as having 3 or more body sites involved. For limited functionality and extensive BSA, 2-tailed χ2 tests with Yates correction were used, except when one of the expected values in the 2 × 2 table is less than 5, in which case the 2-tailed Fisher exact test was used. For mRSS, Localized Scleroderma Skin Severity Index, Localized Scleroderma Skin Damage Index, PGA of Activity, and PGA of Damage, Wilcoxon rank sum tests were used.